City parks may mend the mind

May 20, 2016

Exposure to natural settings has been linked with a vast array of human health benefits, from reduced rates of depression to increased immune functioning. Two recent studies found evidence suggesting that urban green spaces, such as parks and gardens, may also improve cognitive development and buffer against the effects of health inequality.

Spotlight

The shift from volume- to value-based reimbursement is accelerating. Under this evolving paradigm, leading health systems are investing in population health management. An important component of this approach involves next-level risk management for medically complex groups that, despite their low volume, are highly volatile and account for a disproportionately large percentage of overall costs.


Other News
HEALTH TECHNOLOGY

VitalConnect Announces Investment from HCA Healthcare to Accelerate Commercial Growth and Create Strategic Partnership

VitalConnect, Inc. | September 13, 2022

VitalConnect®, Inc., a leader in remote and in-hospital wearable biosensor technology, announced the completion of an investment funded by Health Insight Capital, the investment arm of HCA Healthcare Inc. one of the nation’s leading healthcare providers. The investment will go toward further accelerating VitalConnect’s rapidly growing cardiac monitoring business segment while advancing key Remote Patient Monitoring of individuals who have experienced heart failure (HF), chronic obstructive pulmonary disease (COPD) and sepsis, among others. This funding support is expected to help VitalConnect continue bringing the most advanced technology to patients and providers. “This strategic investment from HCA Healthcare will further accelerate VitalConnect’s expansive growth and upward trajectory in the Cardiac Monitoring space. We’ve experienced unparalleled physician adoption and growth over the past 18 months since launch, and HCA Healthcare’s investment will enable us to continue bringing customers the most comprehensive remote patient monitoring platform.” Peter Van Haur, CEO, VitalConnect Founded in 2011, VitalConnect has deployed hundreds of thousands of biosensors throughout the world, including care facilities such as Brigham and Women’s, Hackensack Medical Center, Northwell Health, and John Radcliffe Hospital-Oxford University. The VitalPatch allows real-time remote or in-hospital monitoring, allowing physicians to optimize the delivery of care to their patients. About VitalConnect, Inc. VitalConnect is a leader in wearable biosensor technology for wireless patient monitoring in both hospital and remote patient populations. VitalConnect leverages extensive expertise in biomedical engineering, data analytics, chip design, and mobile and cloud software to create technology that supports decision-making paradigms that achieve better health and economic outcomes. VitalConnect’s products are designed for use in a broad range of inpatient and outpatient settings, such as hospital monitoring, post-discharge care, cardiac monitoring and pharmaceutical solutions. VitalConnect’s advanced yet easy-to-use platform, was designed to deliver better healthcare at lower costs while providing more convenience for the patients and healthcare providers.

Read More

HEALTH TECHNOLOGY

Prospection partners with leading Japanese healthcare data provider Medical Data Vision to improve treatment access for patients

Prospection | September 06, 2022

Health analytics pioneer, Prospection has announced a unique global data access agreement with leading Japanese medical data company Medical Data Vision Co., Ltd. to accelerate healthcare analytics globally. The agreement, covering the world's second largest pharmaceutical market, will provide global pharmaceutical companies and researchers access to comprehensive and longitudinal data covering more than 40 million people in Japan at more than 470 hospitals. Combining predictive analytics and machine learning with real-world healthcare data, Prospection's agreement with MDV will provide pharmaceutical companies across the world with unique access to patient diagnostic and medication data from hospitals across Japan, unlocking potential to assess an unlimited number of treatment programs in the region. The agreement also enables access to patient history and prefecture level data, allowing analysis of disease progression, disease outcomes and the mapping of disease courses to provide evidence on areas where development can address unmet needs. When distilled further, this creates an opportunity to assess patient data on a regional level to find geographical areas where patients or health centres require additional support for specific disease and conditions. Prospection's access to Japan's most comprehensive medical data sets is a significant milestone for the company. Prospection currently provides real-time access to longitudinal patient data across 15 regions globally including Australia, New Zealand, Japan, South Korea, Taiwan, USA and the UK. The company's latest announcement with Medical Data Vision will build on this work, providing Prospection with access to one of Japan's largest healthcare databases. "We are delighted to announce our latest agreement with Medical Data Vision. This partnership demonstrates a shared commitment to improving patient outcomes and marks a significant milestone in Prospection's mission to deliver real community benefits to patients across the globe. "As one of the largest pharmaceutical markets in the world, Japan has incredibly rich datasets. Working with Medical Data Vision gives us the opportunity to access a dataset of approximately 40 million patients, creating a unique opportunity to use advanced analytic tools to accelerate precision medicine to enable the right patient to receive the right treatment at the right time in their journey. "The outcomes of this partnership will play a key role in understanding the full cycle of patient health conditions and disease journeys in areas including immuno-oncology, immune disorders, cardiovascular and metabolic conditions allowing researchers and pharmaceutical companies globally to better understand the different patient characteristics, treatments and respective outcomes." Eric Chung, CEO and Co-founder, Prospection "We are very excited to be working with MDV in our latest data access agreement. Combining MDV's large and comprehensive dataset with Prospections global reach and extensive expertise working with datasets across the world will not only allow MNC pharmaceutical companies to work with patient data from Japan, but will also open a broader understanding of different health conditions across the world. This agreement brings us one step closer to enhancing precision medicine to find the 40% of patients that can be optimised." About Prospection Prospection is a pioneer in health data analytics technology. We are on a mission to make advancements to precision medicine through real world evidence, with an aim to put the right patient on the right treatment at the right time. Applying advanced ML algorithms to real-world data we unearth health journey and treatment insights by analysing longitudinal data for hundreds of millions of patients to see how drug treatments are used after the clinical trial. Delivering actionable real-world evidence that enables better outcomes for patients, across the world. Prospection is guided by credentialled experts and innovative leaders within their respective fields. Globally, we work with over 15 large health data sets applying our expertise to examine health patterns. Working with government and researchers through to our core client base in the pharma/biopharmaceutical industry, we have delivered insights across more than 90 therapeutic indications. Including rare and complex diseases such as oncology, immuno-oncology, virology, metabolic conditions, respiratory and cardiovascular disease. Prospection is backed by investors including Ellerston, Horizons Ventures and Main Sequence, and commercially with CRO Novotech. About Medical Data Vision (MDV) MDV is an accumulation of anonymously processed data with secondary usage permission from medical institutions. The actual number of patients in the "hospital data" centered on the acute phase is 40.42 million. In addition, by holding data from the health insurance association, data on the recovery period and chronic period has been enhanced, and in addition to information by hospital/clinic, it has become possible to track information on transfer destinations. "Health insurance data" was 7.84 million people (same).

Read More

FUTURE OF HEALTHCARE

Concord Health Partners Adds Healthcare Veteran Brian Gragnolati as Executive Partner

Concord Health Partners | July 12, 2022

Concord Health Partners a healthcare focused investment firm, announced that Brian Gragnolati has joined as Executive Partner. Gragnolati currently serves as President and CEO of Atlantic Health System. During his tenure at Atlantic Health System, he also served as Chairman of the Board of Trustees of the American Hospital Association. The addition of Gragnolati as Executive Partner further expands Concord's team of healthcare sector specialists, adding the network, knowledge and insights of an experienced CEO and a nationally recognized leader in the provider industry. Gragnolati will work with James Olsen, Founder and Managing Partner, and other members of the Concord team to source new investment opportunities, support management teams and accelerate the growth of portfolio companies through commercial introductions across the Concord network of strategic relationships. "We are thrilled to add someone with Brian's experience, knowledge and expertise to Concord's executive team. We established Concord with the goal of creating lasting partnerships with strategic investors to help drive the adoption of our portfolio company technologies and solutions across a broad universe of healthcare providers and payors. Brian brings unique perspective from his roles as a health system chief executive officer and at the AHA, and has distinguished himself as a valuable partner to Concord in those roles. We look forward to leveraging his insights and network as he helps identify new opportunities and accelerate growth at our portfolio companies as Executive Partner." James Olsen, Founder and Managing Partner at Concord "In working with Concord over the years, it was clear that the Firm has developed a powerful model for healthcare investing. Concord has become a leader in identifying innovative companies and partnering with them to drive growth," said Gragnolati. "I am excited at the opportunity to work even more closely with the Concord team and their portfolio companies to help them continue to deliver solutions that lower costs, improve quality and expand access to care." Gragnolati has served as President and CEO of Atlantic Heath System since 2015, and is the former Chairman of the Board of Trustees of the AHA. Prior to his tenure at Atlantic Health, Brian served as Senior Vice President at Johns Hopkins Medicine. He previously held executive positions at Wellspan Health, University of Vermont Medical Center and Baystate Medical Center in Springfield, MA. As a nationally respected voice in health care, Mr. Gragnolati played a key role in public relations and media communications during the COVID pandemic. He regularly appears on CNBC, MSNBC, Bloomberg and other media outlets to share his insight on the nation's most pressing health concerns. He has been honored by Modern Healthcare as one of the 100 most influential people in healthcare. He serves on the Board of Directors of Lakeland Bancorp, Inc. and Lakeland Bank. Gragnolati holds a bachelor's degree in Health Systems Analysis from the University of Connecticut, an MBA from Western New England College and an Executive Leadership Certificate from the JFK School at Harvard University. About Concord Health Partners Concord Health Partners is a healthcare focused investment firm with a strategic model that optimizes the alignment of interests between investors and portfolio companies. Concord has developed a broad network of strategic investors that contribute expertise and resources, and serve as potential commercial partners to portfolio companies. Concord is primarily focused on investing in healthcare companies that have the potential to enhance the value of care through products, services, technologies and solutions that lower costs, improve quality and expand access to care.

Read More

HEALTH TECHNOLOGY

Viemed Announces Publication of Peer-Reviewed NIVH Study Finding Treatment Reduces Healthcare Costs and Saves Lives

Viemed Healthcare, Inc. | July 06, 2022

Viemed Healthcare, Inc. a national leader in respiratory care and technology-enabled home medical equipment services, announced a third peer-reviewed and published study demonstrating the benefits of non-invasive ventilation at home The study, titled “Early Initiation of Non-Invasive Ventilation at Home Improves Survival and Reduces Healthcare Costs in COPD Patients with Chronic Hypercapnic Respiratory Failure: A Retrospective Cohort Study” was published in Respiratory Medicine, an internationally renowned scientific journal devoted to respiratory medical research. “In addition to the significant clinical benefits demonstrated in previously published papers, this study demonstrates that NIVH improves health outcomes while simultaneously driving down overall healthcare costs. The study was also designed to investigate how the timing of NIVH initiation affected the outcomes. The results showed that the clinical and financial benefits of NIVH are greatest when therapy begins immediately following the diagnosis.” Dr. William Frazier, Viemed’s Chief Medical Officer and co-author of the study Using the 100% research identifiable fee-for-service Medicare claims from 2016 through 2020, the researchers found that using NIVH to treat chronic obstructive pulmonary disease with chronic hypercapnic respiratory failure is associated with significant reductions in mortality, hospitalizations, and total Medicare costs. In terms of cost-savings, Medicare expenditures for the year following NIVH initiation decreased by $5,484 compared to controls if treatment was begun within seven days of diagnosis. The cost reduction was $3,412 if NIVH was begun within 15 days of diagnosis. For patients whose therapy began more than 15 days after diagnosis, NIVH use was cost neutral and not associated with an increase in Medicare expenditures. The primary clinical benefit was a reduced mortality in patients treated with NIVH. When a patient began therapy within seven days of diagnosis, the risk of death was reduced by 43%. Those patients who began therapy between eight and 15 days following diagnosis showed a mortality reduction of 31%, and patients who began therapy between 16 and 30 days following diagnosis showed a mortality reduction of 16%. “NIVH is becoming widely accepted by clinicians as the standard of care for hypercapnic COPD-CRF treatment and this evidence supporting early initiation will help us to communicate the clinical and economic benefits to payors and partners,” said Casey Hoyt, Viemed’s CEO. “By accessing and treating more patients sooner, we can save lives, reduce hospital readmissions, and save money at the same time.” ABOUT VIEMED HEALTHCARE, INC. Viemed is a provider of in-home medical equipment and post-acute respiratory healthcare services in the United States. Viemed’s service offerings are focused on effective in-home treatment with clinical practitioners providing therapy and counseling to patients in their homes using cutting edge technology.

Read More

Spotlight

The shift from volume- to value-based reimbursement is accelerating. Under this evolving paradigm, leading health systems are investing in population health management. An important component of this approach involves next-level risk management for medically complex groups that, despite their low volume, are highly volatile and account for a disproportionately large percentage of overall costs.

Resources